Top 5 Psoriasis Content in 2024

In 2024, the most-read psoriasis content included efficacy and safety findings of clinical trials for patients with moderate to severe psoriasis. Here are the top 5 most-read psoriasis articles for this year.

5. Topical PF-07038124 Demonstrates Superior Efficacy in Patients With AD, Plaque Psoriasis

A phase 2a study found that the topical phosphodiesterase 4 inhibitor PF-07038124 was well tolerated and showed superior efficacy in patients with mild to moderate atopic dermatitis (AD) and plaque psoriasis compared with placebo. The treatment resulted in significant improvements in Psoriasis Area and Severity Index (PASI) scores, with no serious adverse events or application site reactions, indicating a favorable safety profile and promising therapeutic potential.

Read the article.

4. Twice-Daily ESK-001 Treatment Shows Majority of Psoriasis Patients Achieve PASI 75

Data from the phase 2 STRIDE trial presented at the European Academy of Dermatology and Venereology 2024 Congress showed that ESK-001, a potent tyrosine kinase (TYK) 2 inhibitor, is highly effective and well tolerated in individuals with moderate to severe plaque psoriasis. Patients receiving the highest dose of 40 mg twice daily achieved 75% clearance, with mild to moderate treatment-emergent adverse events, such as nasopharyngitis and headaches. These findings reinforce the potential of ESK-001 as a promising oral treatment for psoriasis and its ongoing development in phase 3 trials.

Read the article.

Doctor examines patient with psoriasis rash |

Image Credit: ©

ARTFULLY-79 - stock.adobe.com

3. Study Finds Efficiency Frontier Approach Provides Solution to High Drug Prices for Psoriasis in the US

A study suggests that using an efficiency frontier (EF) approach to negotiate drug prices for biologics used to treat psoriasis could lead to significant price reductions while aligning costs with clinical benefits. By comparing 11 biologics and 2 biosimilars, the study found that prices for certain drugs, such as infliximab-dyyb and ixekizumab, could be reduced by up to 71% to match the cost-effectiveness of the most efficient treatments. This approach could help policymakers, insurers, and health managers achieve better alignment of drug prices with their clinical outcomes.

Read the article.

2. Risks of Melanoma, Other Skin Cancers Are Higher in Patients Treated With Biologics for Psoriasis

A meta-analysis study indicated that patients with psoriasis or psoriatic arthritis treated with biologics, includinginterleukin (IL)-17 inhibitors, IL-23 inhibitors, and Janus kinase (JAK) inhibitors, have a higher risk of developing melanoma and nonmelanoma skin cancer compared with the general population. The researchers emphasized the need for long-term cohort studies to further evaluate the safety of these therapies and suggested that guidelines be established for their use, especially in populations at higher risk for skin cancer.

Read the article.

1. TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

A phase 2b clinical trial of zasocitinib, an oral TYK2 inhibitor, demonstrated significant efficacy in treating moderate to severe plaque psoriasis, with up to one-third of patients achieving complete skin clearance after 12 weeks. The treatment showed a favorable safety profile, with no serious adverse events commonly seen with other JAK inhibitors, offering an appealing oral option for patients.

Read the article.